SCHEMBL1032397

SCHEMBL1032397

CC1CCC(Nc2ncc(-c3ccc(OC(C)C)cc3)c(OC(C)(C)C)n2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.41
GABBR2 O75899 1/20 0.37
GABBR1 Q9UBS5 1/20 0.37
CDK4 P11802 1/20 0.36
GSK3B P49841 1/20 0.36
CDK9 P50750 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
ADORA1 P30542 1/20 0.35
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 2/20 0.34
MAP4K4 O95819 1/20 0.34
ATM Q13315 1/20 0.34
ALDH1A1 P00352 3/20 0.34
KDM4E B2RXH2 2/20 0.34
MEN1 O00255 1/20 0.34
HPGD P15428 1/20 0.34
KMT2A Q03164 1/20 0.34
MAPK10 P53779 3/20 0.33
MAPK8 P45983 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1032401 1.00 GRM5 (0.41) GRM5GABBR2GABBR1CDK4GSK3B
SCHEMBL12125236 0.89 GRM5 (0.43) GRM5GABBR2GABBR1CDK4GSK3B
SCHEMBL1032768 0.89 GRM5 (0.43) GRM5GABBR2GABBR1CDK4GSK3B
SCHEMBL1032767 0.89 GRM5 (0.43) GRM5GABBR2GABBR1CDK4GSK3B
SCHEMBL1332866 0.85 GRM5 (0.40) GRM5GABBR2GABBR1CDK4GSK3B
SCHEMBL1332864 0.85 GRM5 (0.40) GRM5GABBR2GABBR1CDK4GSK3B
SCHEMBL1332939 0.85 GRM5 (0.40) GRM5CDK4GSK3BADORA2AADORA2B
SCHEMBL1332938 0.85 GRM5 (0.40) GRM5CDK4GSK3BADORA2AADORA2B
SCHEMBL1032650 0.82 MAPK1 (0.39) GRM5CDK4GSK3BMAPK1MAPK10
SCHEMBL1032647 0.82 MAPK1 (0.39) GRM5CDK4GSK3BMAPK1MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513242-B2 Pyrimidine compounds and methods of making and using same CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2013-08-20 US disclosed
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CYSTIC FIBROSIS FOUNDATION 2011-11-17 US disclosed
WO-2011008931-A2 ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2011-01-20 WO disclosed
WO-2010068863-A2 PYRIMIDINE COMPOUNDS AND METHODS OF MAKING AND USING SAME CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CFTR, GPR17, TYMS GRM5 2764/4885GABBR2 1369/4885GABBR1 1484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.